Weekly Bytes

Weekly Byte

Abstract: “Polymer-fullerene bulk heterojunction solar cells (PSCs) are currently attracting a great deal of attention and gaining increasing importance, having already shown...

Weekly Byte

Abstract: “Organic photovoltaic devices that can be fabricated by simple processing techniques are under intense investigation in academic and industrial laboratories because of their potential to...

Weekly Byte

Abstract: “Simultaneous enhancement of open-circuit voltage, short-circuit current density, and fill factor in highly efficient polymer solar cells by incorporating an alcohol/...

Weekly Byte

“Solution-processed small-molecule solar cells with 6.7% efficiency,” by Yanming Sun, et al., Nature Materials, 11(1): 44-8, January 2012.  

[Authors' affiliations: University of California...

Weekly Byte

Abstract: “To characterize somatic alterations in colorectal carcinoma, we conducted a genome-scale analysis of 276 samples, analysing exome sequence, DNA copy number, promoter methylation and...

Weekly Byte

Abstract: “BACKGROUND Enzalutamide (formerly called MDV3100) targets multiple steps in the androgen-receptor-signaling pathway, the major driver of prostate-cancer growth. We aimed to evaluate...

Weekly Byte

Abstract:“We analysed primary breast cancers by genomic DNA copy number arrays, DNA methylation, exome sequencing, messenger RNA arrays, microRNA sequencing and reverse-phase...

Weekly Byte

Abstract: “BACKGROUND Abiraterone acetate, an androgen biosynthesis inhibitor, improves overall survival in patients with metastatic castration-resistant prostate cancer after...

Weekly Byte

Abstract: “IMPORTANCE More than one-third of adults and 17% of youth in the United States are obese, although the prevalence remained stable between 2003-2004 and 2009-2010...

Weekly Byte

Abstract: “BACKGROUND Infection of poultry with influenza A subtype H7 viruses occurs worldwide, but the introduction of this subtype to humans in Asia has not been observed...

Weekly Byte

Abstract:Background: Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients...

Weekly Byte

Abstract: “BACKGROUND Blockade of programmed death 1 (PD-1), an inhibitory receptor expressed by T cells, can overcome immune resistance. We assessed the antitumor activity and...

Pages